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The presence of oestrogen and progesterone receptors (ER and
PR) is an important prognostic and predictive factor in human
breast cancer. Patients with tumours that express ER and PR
display a less aggressive phenotype with longer disease-free and
overall survival than patients with tumours with no or minimal
ER/PR expression (Knight et al, 1977; Early Breast Cancer
Trialists’ Collaborative Group, 1992). In addition, tumours
bearing hormone receptors (HRs) are more likely to respond to
hormonal therapy (Jordan et al, 1988). In vitro experiments
demonstrated that HR-negative breast cancer cell lines show
increased motility and invasiveness and that invasion and metas-
tasis of ER-positive cells can be blocked by ER-antagonists such
as tamoxifen (Kantor and Zetter, 1996; Rochefort et al, 1998).
Significantly, the precise molecular mechanisms responsible for
the association of increased motility and invasiveness of HR-nega-
tive breast cancer cells in vitro, and the more aggressive pheno-
types observed in the clinic, are unknown. In this regard, however,
increased attention has recently been directed in various cell
systems towards proteins having the capacity to modulate actin
cytoskeleton dynamics (Keely et al, 1997; Carmeci et al, 1998;
Honda et al, 1998).
In this study we analysed the expression of fascin, an actin-
bundling protein associated with cell motility, in immuno-
histochemical sections of breast cancer tissue derived from
HR-negative and HR-positive tumours. Our results demonstrate
that fascin is significantly upregulated in ER- and PR-negative
breast cancer, conceivably contributing to the more malignant
phenotype of HR-negative tumours via effects upon actin based
structures required in cell motility and/or invasion processes.
MATERIAL AND METHODS
Tissue specimens were obtained from 58 female patients (14 pre-,
44 postmenopausal, median age 61 yrs, range 33–85 yrs) with
primary invasive breast cancer. None of the patients had received
preoperative irradiation or chemotherapy. The 58 tumours were
histologically categorized as 38 ductal, 7 lobular, 7 medullar, 2
mucinous, and 4 tubular carcinomas according to the World Health
Organization classification. Normal, non-malignant breast tissue
taken from sites adjacent to cancerous lesions were also collected
for immunostaining. Patient and tumour characteristics are listed
in Table 1.
Formalin-fixed, paraffin-embedded specimens were cut,
dewaxed and blocked with 1% (w/v) bovine serum albumin for
30 minutes. Sections were then incubated with a mouse mono-
clonal anti-human fascin antibody (1:20 dilution; Dako Corp,
Carpinteria, CA) for 16 h at 4°C and immunostained using the
alkaline phosphatase anti-alkaline phosphatase (APAAP) immune
complex method (Universal APAAP kit, Dako) (Pinkus et al,
1997). The binding products were visualized with alkaline phos-
phatase substrate containing naphthol AS-MX phosphate, Fast
Red TR reagents and levamisole as chromogen. Negative controls
were carried out by replacing the primary antibody with normal
mouse lgG1. Slides were counterstained with haematoxylin and
mounted with glycergel (Dako).
Immunohistochemical staining was independently scored by
two observers without the knowledge of all other clinicopatho-
logic features. Discrepant cases were reviewed to achieve a
consensus. The extent and pattern of the staining were each evalu-
ated. Cases were scored as positive when more than 5% of the
tumour cells showed positive staining. Presence of immunoreac-
tivity in more than 50% of cells was scored as diffuse positive.
Borderline staining was defined as positive staining confined to
the outer edges of the tumour clusters. Non-borderline staining
was defined as presence of diffuse staining without apparent
spatial localization.
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Oestrogen and progesterone receptor levels were determined
using a routine enzyme immunoassay (Leclercq et al, 1986).
Tumours were classified as ER- or PR-positive if receptor levels
were ³10 fmol/mg (Sigurdsson et al, 1990). Ploidy of tumour cells
was determined by flow cytometry using a method described
elsewhere (Vindelow et al, 1983).
Statistical analysis was carried out using the Chi-Square-Test
unless otherwise mentioned. Statistical significance was assumed
if P < 0.05.
RESULTS
Forty-eight of 58 breast cancers had ER levels ³ 10 fmol/mg
(= ER-positive), 43 of which (93%) were negative for fascin. In
contrast, in 7 of 10 ER-negative tumours (70%) fascin expression
could be readily demonstrated via immunohistochemical staining.
Statistically, this difference was highly significant (P = 0.0002,
Fisher’s exact test). An inverse correlation between PR and fascin
expression was likewise observed as 39 of 44 (88.6%) PR-positive
and only 7 of 14 (50%) PR-negative tumours showed a negative
staining reaction for fascin (P = 0.0047, Fisher’s exact test)
(Figure 1A). All 6 tumours negative for ER and PR were fascin
positive in contrast to only 4 of 40 (10%) tumours positive for ER
and PR (Figure 1B). As expected, ER and PR levels were well
correlated (P = 0.0032, Spearman test). Fascin expression showed
no significant correlation with menopause status, tumour stage,
histology, grading, number of lymph nodes involved, presence of
metastasis at time of surgery, CEA and CA15–3 levels. However,
flow cytometry analysis revealed that fascin negative tumors
were more likely diploid (26 of 43 (60.5%)) than non-diploid
(17 of 43 (39.5%)), a difference that reached statistical signifi-
cance (P = 0.03). No significant correlation was found
between histological tumour grading and ploidy (P = 0.12).
Immunohistochemically, fascin positivity appeared as cytoplasmic
staining with a marked enhancement in areas of tumour–host
interaction in most samples (Figure 2).
DISCUSSION
It is well-known that ER-negative breast cancers display a more
aggressive behaviour than ER-positive tumours. As regulation of
the actin cytoskeleton plays a crucial role in cell motility and
cancer invasion, molecular modulators of actin dynamics might be
anticipated to contribute to the malignant phenotype of cancer
cells. In the context of normal cells, for example, it is well
accepted that the plasticity of the cytoskeleton is modulated via the
activities of actin-associated proteins (Mitchison and Cramer,
1996).
Proteins that are capable of bundling or binding actin filaments
are numerous and include fimbrin, various tropomyosin isoforms,
gelsolin, a-actinin, and a-catenin (Otto, 1994). Early studies iden-
tified changes in the organization of the cytoskeleton and junc-
tional proteins in cancer cells, largely indicating a reduction in the
expression of actin associated proteins (Ben-Ze’ev, 1985; Asch
et al, 1996). In addition, it has been shown that restoration of
vinculin and a-actinin expression in cancer cells results in
decreased tumorigenicity and metastatic properties (Rodriguez
Fernandez et al, 1992; Gluck et al, 1993).
Table 1 Patient and tumour characteristics
Number of patients
Total 58
Median age (range) 61 yrs (33–85)
Premenopausal 14
Postmenopausal 44
Histology (fascin positive tumours)
ductal 38 (8)
lobular 7 (1)
medullary 7 (2)
mucinous 2 (0)
tubular 4 (1)
Stage
T1 22
T2 27
T3 2
T4 7
N0 29
N1 21
N2 7
NX 1
M0 51
M1 7
Receptor status
ER positive 48
ER negative 10
PR positive 44
PR negative 14
100%
60%
40%
20%
0%
80%
ER pos ER neg PR pos PR neg
5 5
43 39
7
3
7
7
4
36 7
3
6
1
1
fascin pos
fascin neg
=0.0002 =0.0047 P
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Figure 1 Differential expression of fascin in ER- or PR-positive and
-negative breast cancers. Numbers in bars reflect the absolute number of
cases. Statistical evaluation by Fisher’s exact test (panel A) or Chi-square
test (panel B)872 A Grothey et al
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More recently, however, various proteins that modulate
dynamic properties of the actin cytoskeleton have been associated
with an increased malignant potential in tumour cells, namely the
small G-proteins Rac, Rho, and cdc42, the guanine nucleotide
exchange factor Tiam-1, EMS1, and actinin-4 (del Peso et al,
1997; Hordijk et al, 1997; Hui et al, 1997; Keely et al, 1997;
Honda et al, 1998). Further, the actin-binding protein moesin, a
member of the talin-4.1 superfamily was found to be associated
with the ER-negative breast cancer phenotype (Carmeci et al,
1998). Similar to fascin, moesin is localized in filopodia and other
subcellular structures engaged in active cell motility processes
(Amieva and Furthmayr, 1995).
Fascin possess two actin-binding domains within a single mole-
cule, permitting tight packing of filamentous actin (Tilney et al,
1995). Fascin has been found in highly motile and dynamic
subcellular structures such as microspikes, lamellipodia, and
filopodia (Edwards and Bryan, 1995). The overexpression of
native human fascin in a pig epithelial cell line (LLC-PK1) was
associated with reduced cell–cell junction integrity, the develop-
ment of a fibroblastic phenotype, and increased cell motility
(Yamashiro et al, 1998), which has recently been correlated with
phosphorylation of fascin on serine 39 (Adams et al, 1999).
Reduced junctional integrity has likewise been associated with
increased fascin expression in the absence of glucocorticoids
(Wong et al, 1997), again consistent with reduced adhesion and
increased motility in cells expressing relatively greater levels of
fascin. Our own experiments, to date published in abstract form,
have revealed that fascin exhibits highly increased levels in breast
cancer cell lines over-expressing the receptor tyrosine kinase and
prognostic indicator c-erbB-2/HER-2, and that such cells exhibit
dramatically increased cell dynamics and in vitro motility
(Grothey et al, in press).
In this study we demonstrate that the expression of fascin is
clearly associated with the absence of ER and PR in invasive
breast carcinomas. Moreover, fascin is preferentially expressed in
non-diploid tumours although no correlation with the histological
grading could be observed. Histologically, fascin staining is often
enhanced at the leading edges of infiltrating tumours, which indi-
cates its role as a pathogenic factor for tumour cell invasion. The
molecular mechanism leading to the increased expression of fascin
in HR-negative breast carcinomas is presently unknown, and work
is in progress to analyse the effect of steroid hormones on fascin’s
transcriptional regulation (GenBank accession number U90355,
submitted February 24, 1997, by Tubb BE, Lee R, and Bryan J).
In conclusion, ER-and PR-negative breast cancers are character-
ized by an increased expression of the actin-bundling, motility-
associated protein fascin. It is conceivable that fascin may serve as
a downstream cytoskeletal effector contributing to the more
aggressive/malignant phenotype of HR-negative breast cancer.
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